Group 1 - The company,诺禾致源, reported a total operating revenue of 2,209.64 million yuan for the year 2025, representing a year-on-year increase of 4.66% [2] - The net profit attributable to the parent company's owners for 2025 was 166.11 million yuan, showing a year-on-year decrease of 15.59% [2]

Core Viewpoint - The company reported a total operating revenue of 2.21 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 4.66%, despite a decline in net profit attributable to shareholders [1] Financial Performance - The net profit attributable to shareholders was 166 million yuan, representing a year-on-year decrease of 15.59% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 128 million yuan, down 24.75% year-on-year [1] - Total assets at the end of the reporting period reached 3.98 billion yuan, an increase of 9.50% compared to the end of 2024 [1] - Shareholders' equity attributable to the parent company was 2.65 billion yuan, up 6.33% from the end of 2024 [1] Strategic Initiatives - The company is actively responding to macroeconomic challenges and fluctuations in client funding, managing to achieve stable revenue growth [1] - To seize long-term market opportunities, the company is significantly increasing its R&D investment, focusing on AI-enabled research, single-cell and spatial multi-omics, protein and metabolomics solutions, and clinical translation [1]

Financial Performance - Total revenue for 2025 reached RMB 2,209.64 million, a year-on-year increase of 4.66%[3] - Net profit attributable to shareholders was RMB 166.11 million, a decrease of 15.59% compared to the previous year[3] - Net profit excluding non-recurring gains and losses was RMB 128.49 million, down 24.75% year-on-year[3] - Basic earnings per share decreased to RMB 0.41, down 14.58% from RMB 0.48[3] Assets and Equity - Total assets at the end of the reporting period were RMB 3,982.45 million, an increase of 9.50% from the end of 2024[4] - Shareholders' equity attributable to the parent company was RMB 2,647.53 million, up 6.33% from the previous year[4] Research and Development - The company increased R&D investment, focusing on AI-enabled research and cutting-edge solutions in single-cell and spatial multi-omics[6] Management and Strategy - Management efficiency improvements led to a reduction in management expense ratio, with resources redirected towards global market expansion[7] - The company aims to build sustainable profitability by investing in advanced technologies to meet customer needs[7] Reporting Accuracy - There are no significant uncertainties affecting the accuracy of the performance report[8]

Group 1 - The core viewpoint of the news is that 诺禾致源 (Nuohe Zhiyuan) has shown mixed financial performance, with a slight increase in revenue but a significant decrease in net profit [2][3] - As of February 24, 2025, 诺禾致源's stock price decreased by 0.52%, with a trading volume of 56.18 million yuan and a net financing purchase of 5.83 million yuan [1] - The company's financing balance reached 144 million yuan, accounting for 2.27% of its market capitalization, indicating a high level of financing activity compared to the past year [1] Group 2 - For the period from January to September 2025, 诺禾致源 reported a revenue of 1.581 billion yuan, representing a year-on-year growth of 4.05% [2] - The net profit attributable to shareholders for the same period was 113 million yuan, reflecting a year-on-year decrease of 16.05% [2] - The company has distributed a total of 82.47 million yuan in dividends since its A-share listing, with 58.45 million yuan distributed over the past three years [3]

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

北京诺禾致源科技股份有限公司 内部审计制度 二〇二六年一月 （三）保障公司资产的安全； 第一章 总则 第一条 为了加强和规范北京诺禾致源科技股份有限公司（以下简称"公 司"）内部审计工作，明确内部审计职责，建立健全有效的内部监督体系，提高 公司抗风险能力，根据《中华人民共和国审计法》《上海证券交易所科创板股票 上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等相关法律法规，结合本公司实际情况，特制定本度。 第二条 本制度所称内部审计，是指公司内部审计机构或人员依据国家有关 法律法规和本制度的规定，对本公司各内部机构、控股子公司以及具有重大影响 的参股公司的内部控制和风险管理的有效性、财务信息的真实性、完整性以及经 营活动的效率和效果等开展的一种评价活动。 第三条 本制度所称内部控制，是指公司董事会、审计委员会、高级管理 人员及其他有关人员为实现下列目标而提供合理保证的过程： （一）遵守国家法律、法规、规章及其他相关规定； （四）确保公司信息披露的真实、准确、完整和公平。 北京诺禾致源科技股份有限公司 内部审计制度 （二）提高公司经营的效率和效果； 第四条 公司董事会应当对内部控制 ...

Core Viewpoint - The medical services sector experienced a rise of 1.19% on January 23, with notable gains from companies like Nuohua Zhiyuan, which led the sector's performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1]. - The medical services sector saw significant individual stock movements, with Nuohua Zhiyuan (688315) closing at 17.00, up 13.26%, and Hai Te Biological (300683) closing at 33.31, up 7.66% [1]. Group 2: Trading Volume and Value - Nuohua Zhiyuan had a trading volume of 219,500 shares and a transaction value of 365 million yuan [1]. - Hai Te Biological recorded a trading volume of 190,900 shares with a transaction value of 632 million yuan [1]. Group 3: Capital Flow - The medical services sector saw a net inflow of 999.1 million yuan from institutional investors, while retail investors experienced a net outflow of 1.069 billion yuan [2]. - The capital flow data indicates that major stocks like Diyan Diagnosis (300244) had a net inflow of 288 million yuan from institutional investors [3].

Group 1 - The Shanghai Composite Index closed at 4136.16 points, above the five-day moving average, with a gain of 0.33% [1] - The total trading volume of A-shares reached 31,181.08 billion yuan [1] - A total of 1,091 A-shares have prices that surpassed the five-day moving average, with notable stocks including Dongfang Risheng, Jinko Solar, and Xinke Mobile, showing divergence rates of 16.59%, 15.85%, and 15.78% respectively [1] Group 2 - The top stocks with significant divergence rates from the five-day moving average include: - Dongfang Risheng (300118) with a price increase of 20.00% and a divergence rate of 16.59% [1] - Jinko Solar (688223) also increased by 20.00% with a divergence rate of 15.85% [1] - Xinke Mobile (688387) rose by 18.41% with a divergence rate of 15.78% [1] - Other notable stocks with divergence rates include: - Jiejia Weichuang (300724) at 20.00% increase and 15.34% divergence [1] - Ruichuang Micro (688002) with a 20.00% increase and 14.83% divergence [1]

Core Viewpoint - The A-share market shows positive momentum with the Shanghai Composite Index closing at 4133.58 points, above the five-day moving average, reflecting a gain of 0.27% [1] Group 1: Market Performance - The total trading volume of A-shares reached 19,136.04 billion yuan [1] - A total of 961 A-shares have prices that surpassed the five-day moving average [1] Group 2: Individual Stock Performance - Notable stocks with significant deviation rates from the five-day moving average include: - Dongfang Risheng (300118) with a deviation rate of 16.59% and a price increase of 20.00% [2] - Jiejia Weichuang (300724) with a deviation rate of 15.34% and a price increase of 20.00% [2] - Ruichuang Weina (688002) with a deviation rate of 14.83% and a price increase of 20.00% [2] - Other stocks with notable performance include: - Jingke Energy (688223) with a deviation rate of 14.43% and a price increase of 18.09% [2] - Guosheng Tang (300436) with a deviation rate of 14.19% and a price increase of 20.00% [2]

Market Overview - The medical services sector increased by 0.18% on January 21, with Nanmo Biology leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Gainers in Medical Services - Nanmo Biology (688265) closed at 49.79, up 7.01% with a trading volume of 20,000 shares and a transaction value of 98.02 million [1] - Hite Biology (300683) closed at 29.67, up 5.74% with a trading volume of 107,800 shares and a transaction value of 32.2 million [1] - Dean Diagnostics (300244) closed at 26.46, up 5.59% with a trading volume of 796,300 shares and a transaction value of 2.13 billion [1] - ST Zhongzhu (600568) closed at 2.64, up 5.18% with a trading volume of 376,500 shares and a transaction value of 9.81 million [1] - Tongce Medical (600763) closed at 46.51, up 4.99% with a trading volume of 198,600 shares and a transaction value of 911 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 18.72, down 4.44% with a trading volume of 74,500 shares and a transaction value of 143 million [2] - Hongbo Pharmaceutical (301230) closed at 46.36, down 1.88% with a trading volume of 131,200 shares and a transaction value of 614 million [2] - Chengda Pharmaceutical (301201) closed at 41.39, down 1.76% with a trading volume of 36,600 shares and a transaction value of 153 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 50.51 million from institutional investors, while retail investors experienced a net outflow of 375 million [2] - The sector's overall capital flow indicates a strong interest from institutional and speculative investors, with retail investors pulling back [2][3] Notable Capital Inflows - Sanbo Brain Science (301293) had a net inflow of 91.48 million, representing 9.03% of its total capital [3] - Tongce Medical (600763) saw a net inflow of 83.46 million, accounting for 9.16% of its total capital [3] - BGI Genomics (300676) recorded a net inflow of 51.81 million, which is 8.37% of its total capital [3]